drugset / Trial / NCT00973349

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

NCT00973349 ↗

Phase 2/3 Completed 2719 enrolled Novartis Novartis Vaccines · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in non-elderly and elderly adults.

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MF59-eH1N1_f Vaccine 3.75 ug —
Subject MF59-eH1N1_f Vaccine 7.5 ug —
Subject MF59-eH1N1_f Vaccine 15 ug —
Subject MF59-eH1N1_f Vaccine 30 ug —

Indications